Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AMLX vs AVDL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–3 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: AMLX 1 – 4 AVDL (1 Tie) Matrix Metrics: AMLX 3 – 6 AVDL

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Amylyx Pharmaceuticals, Inc. (AMLX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AMLX carries a Unified Composite Score of 51.4/100 (HOLD) at $26.02 (2.8x Forward P/E, 0.0% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin).

  • Technical & Structure Timing Caution: AMLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.5); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AMLX vs AVDL
AMLX NASDAQ
Amylyx Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$26.02
-0.69% 1D
Market Cap $3.4B
TTM Revenue N/A
Forward P/E 2.8x
Beta / 30D Vol 1.10β · 60% Vol
Unified Composite Score
51.4 / 100 HOLD
Tech 19.0 Fund 46.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.9%), weak momentum, RSI 39
RSI-14: 39.5 · SMA20: $28.60 · SMA50: $29.05
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50

6-Pillar Scorecard Institutional Category Breakdown (AMLX 1 – 4 AVDL)

Columns: Metric · AMLX · AVDL
1. Valuation Multiples AMLX
Forward P/E 2.8x 28.8x
Trailing P/E 2.8x 16.8x
PEG Ratio N/M 0.07x
EV / Revenue N/M 8.5x
2. Growth & Scale AVDL
Revenue Growth (YoY) -99.6% +54.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $249M
Market Cap $3.4B $2.1B
3. Profitability & Quality AVDL
Gross Margin N/A 94.9%
Operating Margin 0.0% 2.5%
Net Profit Margin 0.0% -0.1%
Return on Equity (ROE) -30.1% -0.3%
4. Balance Sheet & Cash Flow AVDL
Cash Generation (TTM) -$130M $2.7M EBITDA
Cash Flow Margin N/A 1.1% EBITDA Mgn
Net Cash / Leverage $235M Net Cash $1.01 Book/Sh · -0.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVDL
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 203.4% (32nd %ile) 2.4% (<1st %ile)
Put/Call OI Skew 0.52x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AMLX (3) vs AVDL (6)
Institutional Metric AMLX AVDL Criterion Row Edge
Market Capitalization
Scale
$3.4B $2.1B Larger Scale AMLX
Trailing P/E Ratio
Valuation
2.8x 16.8x Lower Multiple AMLX
Forward P/E Ratio
Valuation
2.8x 28.8x Lower Multiple AMLX
Revenue Growth (YoY)
Growth
-99.6% +54.9% Higher Growth AVDL
Operating Margin (TTM)
Profitability
0.0% 2.5% Higher Margin AVDL
Net Profit Margin
Profitability
0.0% -0.1% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-30.1% -0.3% Higher ROE AVDL
52-Week Range Position
Momentum
50% ($11–$41) 89% ($6–$24) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
1.10β · 60% Vol 0.14β · 2% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
51.4 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
N/A $249M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 94.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.07x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$130M ($235M Net Cash) $2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AMLX +15.17 pp
AMLX: +15.82% · AVDL: +0.65%
3M Horizon AMLX +6.53 pp
AMLX: +0.21% · AVDL: -6.32%
6M Horizon AMLX +6.53 pp
AMLX: +0.21% · AVDL: -6.32%
1Y Horizon AMLX +6.53 pp
AMLX: +0.21% · AVDL: -6.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AMLX vs AVDL. Trailing 12-month operating profitability (AMLX 0.0% vs AVDL 2.5%) and valuation multiples (AMLX 2.8x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

AMLX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-30.1% · 2.8x
AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AMLX BREAKDOWN
65d in phase · OBV DISTRIBUTION
Current IV 203.4%
IV Percentile 32nd %ile
Put/Call OI Skew 0.52x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AMLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AMLX Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AMLX vs AVDL Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Amylyx Pharmaceuticals, Inc. (AMLX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AMLX carries a Unified Composite Score of 51.4/100 (HOLD) at $26.02 (2.8x Forward P/E, 0.0% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin). Technical & Structure Timing Caution: AMLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.5); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVDL leads the Growth & Scale pillar: AMLX posts -99.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, AMLX generates N/A in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, AMLX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.

AMLX screens cheaper on headline valuation multiples. AMLX trades at 2.8x Forward P/E, 2.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMLX (-30.1% ROE) versus AVDL (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, AMLX carries 203.4% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.10β · 60% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.